Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Novel Biomarkers and Therapeutic Targets for Melanoma

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 13217

Share This Special Issue

Special Issue Editors

Dr. Valentina Audrito

E-Mail Website
Guest Editor

Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy
Interests: malignant melanoma; metabolic reprogramming; NAD-metabolizing enzymes; biomarker; microenvironment; therapy resistance; translational oncology
Special Issues, Collections and Topics in MDPI journals

Dr. Alice Indini

E-Mail Website
Guest Editor

Medical Oncology Unit, Ospedale di Circolo e Fondazione Macchi, ASST dei Settelaghi, Varese, Italy
Interests: melanoma; skin cancer; immunotherapy; targeted therapy; BRAF; MEK; resistance mechanisms

Special Issue Information

Dear Colleagues,

Malignant melanoma represents the most fatal skin cancer due to its aggressive biological behavior and high metastatic potential. Treatment strategies for advanced disease have dramatically changed over the last years, due to the introduction of BRAF/MEK inhibitors and immunotherapy. However, many patients either display primary (i.e., innate), or develop secondary (i.e., acquired) resistance to systemic treatments. Resistance is due to many complex and multiple mechanisms driven by a set of rewiring processes, which involve cancer metabolism, epigenetics, gene expression and interactions in the tumor microenvironment. Prognostic and predictive biomarkers are still needed to guide patients’ selection and treatment decisions. Indeed, there are no recognized clinical or biological characteristics that identify which patients will benefit more from available treatments, but several biomarkers have been studied with promising preliminary results.

In this Special Issue, we welcome research articles and reviews analyzing new insights into the molecular and cellular mechanisms underlying the progression of melanoma and the response to therapy, focusing on prognostic factors, biomarkers for risk stratification, treatment response and prognosis, and novel therapeutic strategies in the field of melanoma.

Dr. Valentina Audrito
Dr. Alice Indini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

melanoma
biomarkers
therapeutic targets
targeted therapy
immunotherapy
resistance
genetics
phenotype plasticity

Published Papers (5 papers)

Download All Papers

Research

Jump to: Review

17 pages, 3960 KiB

Open AccessArticle

The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition

by Luca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi, Jan Viehof, Ágnes Enyedi, Ágnes Bilecz, Balázs Győrffy, Marcell Baranyi, Anna-Mária Tőkés, Jeovanis Gil, György Marko-Varga, Klaus G. Griewank, Lisa Zimmer, Renáta Váraljai, Antje Sucker, Anne Zaremba, Dirk Schadendorf, Clemens Aigner and Balázs Hegedüs

Int. J. Mol. Sci. 2022, 23(6), 3324; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23063324 - 19 Mar 2022

Cited by 4 | Viewed by 2040

Abstract

PMCA4 is a critical regulator of Ca²⁺ homeostasis in mammalian cells. While its biological and prognostic relevance in several cancer types has already been demonstrated, only preclinical investigations suggested a metastasis suppressor function in melanoma. Therefore, we studied the expression pattern of PMCA4 in human skin, nevus, as well as in primary and metastatic melanoma using immunohistochemistry. Furthermore, we analyzed the prognostic power of PMCA4 mRNA levels in cutaneous melanoma both at the non-metastatic stage as well as after PD-1 blockade in advanced disease. PMCA4 localizes to the plasma membrane in a differentiation dependent manner in human skin and mucosa, while nevus cells showed no plasma membrane staining. In contrast, primary cutaneous, choroidal and conjunctival melanoma cells showed specific plasma membrane localization of PMCA4 with a wide range of intensities. Analyzing the TCGA cohort, PMCA4 mRNA levels showed a gender specific prognostic impact in stage I–III melanoma. Female patients with high transcript levels had a significantly longer progression-free survival. Melanoma cell specific PMCA4 protein expression is associated with anaplasticity in melanoma lung metastasis but had no impact on survival after lung metastasectomy. Importantly, high PMCA4 transcript levels derived from RNA-seq of cutaneous melanoma are associated with significantly longer overall survival after PD-1 blockade. In summary, we demonstrated that human melanoma cells express PMCA4 and PMCA4 transcript levels carry prognostic information in a gender specific manner. Full article

(This article belongs to the Special Issue Novel Biomarkers and Therapeutic Targets for Melanoma)

► Show Figures

Figure 1

19 pages, 4451 KiB

Open AccessArticle

Salviolone from Salvia miltiorrhiza Roots Impairs Cell Cycle Progression, Colony Formation, and Metalloproteinase-2 Activity in A375 Melanoma Cells: Involvement of P21(Cip1/Waf1) Expression and STAT3 Phosphorylation

by Valentina Zanrè, Rachele Campagnari, Antonietta Cerulli, Milena Masullo, Alessia Cardile, Sonia Piacente and Marta Menegazzi

Int. J. Mol. Sci. 2022, 23(3), 1121; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23031121 - 20 Jan 2022

Cited by 6 | Viewed by 2201

Abstract

Melanoma is a highly malignant solid tumor characterized by an elevated growth and propagation rate. Since, often, melanoma treatment cannot prevent recurrences and the appearance of metastasis, new anti-melanoma agents need to be discovered. Salvia miltiorrhiza roots are a source of diterpenoid derivatives, natural compounds with several biological activities, including antiproliferative and anticancer effects. Seven diterpenoid derivatives were purified from S. miltiorrhiza roots and identified by NMR and MS analysis. Tanshinone IIA and cryptotanshinone were detected as the main components of S. miltiorrhiza root ethanol extract. Although their antitumor activity is already known, they have been confirmed to induce a reduction in A375 and MeWo melanoma cell growth. Likewise, salviolone has been shown to impair the viability of melanoma cells without affecting the growth of normal melanocytes. The underlying anticancer activity of salviolone has been investigated and compared to that of cryptotanshinone in A375 cells, showing an increased P21 protein expression in a P53-dependent manner. In that way, salviolone, even more than cryptotanshinone, displays a multitarget effect on cell-cycle-related proteins. Besides, it modulates the phosphorylation level of the signal transducer and activator of transcription (STAT)3. Unexpectedly, salviolone and cryptotanshinone induce sustained activation of the extracellular signal-regulated kinases (ERK)1/2 and the protein kinase B (Akt). However, the blockage of ERK1/2 or Akt activities suggests that kinase activation does not hinder their ability to inhibit A375 cell growth. Finally, salviolone and cryptotanshinone inhibit to a comparable extent some crucial malignancy features of A375 melanoma cells, such as colony formation in soft agar and metalloproteinase-2 activity. In conclusion, it has been shown for the first time that salviolone, harboring a different molecular structure than tanshinone IIA and cryptotanshinone, exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells. Full article

(This article belongs to the Special Issue Novel Biomarkers and Therapeutic Targets for Melanoma)

► Show Figures

Figure 1

Review

Jump to: Research

10 pages, 271 KiB

Open AccessReview

Novel Biomarkers and Therapeutic Targets for Melanoma

by Noa Sabag, Alexander Yakobson, Meir Retchkiman and Eldad Silberstein

Int. J. Mol. Sci. 2022, 23(19), 11656; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231911656 - 01 Oct 2022

Cited by 5 | Viewed by 1678

Abstract

Malignant melanoma is one of the most common cancers in the world. In the disease’s early stages, treatment involves surgery, in advanced stages however, treatment options were once scarce. There has been a paradigm shift in advanced melanoma treatment with the introduction of immunotherapy and targeted therapies. Understanding the molecular pathways and their pathologic counterparts helped identifying specific biomarkers that lead to the development of specific targeted therapies. In this review we briefly present some of these markers and their relevance to melanoma treatment. Full article

(This article belongs to the Special Issue Novel Biomarkers and Therapeutic Targets for Melanoma)

33 pages, 2339 KiB

Open AccessReview

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

by Alice Indini, Irene Fiorilla, Luca Ponzone, Enzo Calautti and Valentina Audrito

Int. J. Mol. Sci. 2022, 23(17), 9985; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23179985 - 01 Sep 2022

Cited by 9 | Viewed by 3865

Abstract

Malignant melanoma represents the most fatal skin cancer due to its aggressive behavior and high metastatic potential. The introduction of BRAF/MEK inhibitors and immune-checkpoint inhibitors (ICIs) in the clinic has dramatically improved patient survival over the last decade. However, many patients either display primary (i.e., innate) or develop secondary (i.e., acquired) resistance to systemic treatments. Therapeutic resistance relies on the rewiring of multiple processes, including cancer metabolism, epigenetics, gene expression, and interactions with the tumor microenvironment that are only partially understood. Therefore, reliable biomarkers of resistance or response, capable of facilitating the choice of the best treatment option for each patient, are currently missing. Recently, activation of nicotinamide adenine dinucleotide (NAD) metabolism and, in particular, of its rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT) have been identified as key drivers of targeted therapy resistance and melanoma progression. Another major player in this context is the mammalian target of rapamycin (mTOR) pathway, which plays key roles in the regulation of melanoma cell anabolic functions and energy metabolism at the switch between sensitivity and resistance to targeted therapy. In this review, we summarize known resistance mechanisms to ICIs and targeted therapy, focusing on metabolic adaptation as one main mechanism of drug resistance. In particular, we highlight the roles of NAD/NAMPT and mTOR signaling axes in this context and overview data in support of their inhibition as a promising strategy to overcome treatment resistance. Full article

(This article belongs to the Special Issue Novel Biomarkers and Therapeutic Targets for Melanoma)

► Show Figures

Figure 1

18 pages, 1257 KiB

Open AccessReview

Role of HMGB1 in Cutaneous Melanoma: State of the Art

by Federica Li Pomi, Francesco Borgia, Paolo Custurone, Mario Vaccaro, Giovanni Pioggia and Sebastiano Gangemi

Int. J. Mol. Sci. 2022, 23(16), 9327; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23169327 - 18 Aug 2022

Cited by 15 | Viewed by 2468

Abstract

High-mobility Group Box 1 (HMGB1) is a nuclear protein that plays a key role in acute and chronic inflammation. It has already been studied in several diseases, among them melanoma. Indeed, HMGB1 is closely associated with cell survival and proliferation and may be directly involved in tumor cell metastasis development thanks to its ability to promote cell migration. This research aims to assess the role of this molecule in the pathogenesis of human melanoma and its potential therapeutic role. The research has been conducted on the PubMed database, and the resulting articles are sorted by year of publication, showing an increasing interest in the last five years. The results showed that HMGB1 plays a crucial role in the pathogenesis of skin cancer, prognosis, and therapeutical response to therapy. Traditional therapies target this molecule indirectly, but future perspectives could include the development of new target therapy against HMGB1, thus adding a new approach to the therapy, which has often shown primary and secondary resistance. This could add a new therapy arm which has to be prolonged and specific for each patient. Full article

(This article belongs to the Special Issue Novel Biomarkers and Therapeutic Targets for Melanoma)

► Show Figures